RVV and RVVTF Related Headlines

Go Back

Sep 15, 2026 09:35AM Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases

Nov 21, 2025 12:07PM Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

RVV and RVVTF Related Press Releases

Go Back

Sep 15, 2026 09:35AM Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases

Nov 21, 2025 12:07PM Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

RVV and RVVTF Related SEC Filings

Go Back